Boyd, A. M.; Marks, J.
April 1963
Angiology;Apr1963, Vol. 14 Issue 4, p198
Academic Journal
A blind controlled trial was carried out to study the effect of α-tocopherol in a group of patients with intermittent claudication. After a trial period lasting 13 weeks, the effect of treatment was assessed by (1) the walking distance before the onset of pain and (2) the total walking distance before the patient had to come to a halt. The results showed that the difference between the effect of a-tocopherol and that of a matching placebo was statistically significant thus confirming two previous reports. The difficulties in assessing the response to therapy in intermittent claudication and the previous contradictory reports about the value of a-tocopherol are discussed. A series of 1476 patients was followed up in order to study their survival rate, and it was shown that these patients, all of whom had received α-tocopherol for a prolonged period, lived longer than similar groups of patients who had not received this therapy. The possible mode of action of a-tocopherol is discussed, and it is concluded that it probably improves muscle metabolism by the maintenance of certain factors essential for the normal metabolic cycle.


Related Articles

  • Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study. Norgren, L; Jawien, A; Mátyás, L; Rieger, H; Arita, K; The European MCI-9042 Study Group // Vascular Medicine;2006, Vol. 11 Issue 2, p75 

    This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent...

  • Naftidrofuryl: A Review of its Use in the Treatment of Intermittent Claudication. Goldsmith, David R.; Wellington, Keri // Drugs & Aging;2005, Vol. 22 Issue 11, p967 

    Naftidrofuryl (Praxilene®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...

  • A Double-Blind, Placebo-Controlled Study of the Effects of Policosanol in Patients with Intermittent Claudication. Castaño, Gladys; Más, Rosa; Roca, Juan; Fernández, Lilia; Illnait, José; Fernandez, Julio César; Selman, Eugenio // Angiology;Feb1999, Vol. 50 Issue 2, p123 

    This study was undertaken to evaluate the efficacy and tolerability of policosanol, a new cholesterol-lowering drug with concomitant antiplatelet effects, in patients with intermittent claudication. After a baseline period of 6 weeks, 62 patients were randomized to receive, under double-blind...

  • Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study. Ilinait, José; Castaflo, Gladys; Alvarez, Ernesto; Fernández, Lilia; Mas, Rosa; Mendoza, Sarahi; Gamez, Rafael // Angiology;Jun/Jul2008, Vol. 59 Issue 3, p269 

    Antiplatelet therapy, including aspirin, is recommended to lower the vascular risk in patients with intermittent claudication. Policosanol has increased walking distances in these patients, probably because of its antiplatelet effects, but the effect of shorter treatment has not been studied....

  • Independent Nurse: Clinical CVD - Managing a case of peripheral arterial disease. Shearman, Cliff // GP: General Practitioner;12/11/2009, p34 

    The article presents a case study of a 60 year old man with complaint of bilateral calf claudication after walking about 30 metres. It states the man was diagnosed with type-1 diabetes at age 19 and at age 48 was diagnosed with hypertension and later was investigated for intermittent...

  • Effects of Ethaverine Hydrochloride on the Walking Tolerance of Patients with Intermittent Claudication. Trainor, Frieda S.; Phillips, Raymond E.; Michie, David D.; Zellner, Stephen R.; Hogan, Jr, Leo; Chubb, James M. // Angiology;May1986, Vol. 37 Issue 5, p343 

    The effect of ethaverine hydrochloride on excercise tolerance of patients with intermittent claudication was evaluated in a double-blind, placebo-controlled study conducted at three sites. Forty-five patients with symptoms of occlusive arterial insufficiency of the lower extremities were...

  • Placebo-Controlled Trial of Ketanserin in the Treatment of Intermittent Claudication. Cameron, H. A.; Waller, P. C.; Ramsay, L. E. // Angiology;Jul1987, Vol. 38 Issue 7, p549 

    The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months'...

  • Double-Blind Study of Papaverine Hydrochloride on the Efficacy in the Treatment of Intermittent Claudication. Seino, Yoshihiko; Rose, Harold B.; Kanazawa, Masakuni; Vyden, John K.; Wall, Francis J. // Angiology;Apr1983, Vol. 34 Issue 4, p257 

    A double-blind, placebo-controlled, parallel groups study design was utilized to evaluate the efficacy and the safety of papaverine HCL (PA, 300-1,500 mg/day) in the treatment of intermittent claudication. The study was in two phases: Phase 1-6 weeks duration with treadmill claudication tests...

  • Propionyl-l-carnitine for intermittent claudication. Deckert, James // Journal of Family Practice;Jun1997, Vol. 44 Issue 6, p533 

    The article discusses research being done on the effect of propionyl-L-carnitine on the quality of life in intermittent claudication, with reference to a study by G. Brevetti, S. Perna, C. Sabba et al, which appeared in the 1997 issue of the "American Journal of Cardiology." Patients included...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics